Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China flag China · Delayed Price · Currency is CNY
22.67
-0.81 (-3.45%)
Aug 26, 2026, 3:04 PM CST

Hybio Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
126.7436.57-173.65-513.88-370.5530.81
Depreciation & Amortization
145.71131.17148.27155.54140.59135.78
Other Amortization
7.77.862.654.93.893.7
Loss (Gain) From Sale of Assets
-1.65-0.62-42.780.51-3.41-35.2
Asset Writedown & Restructuring Costs
20.9212.4582.4399.9423.0575.31
Loss (Gain) From Sale of Investments
-65.75-1.5-1.55-43.8386.06-372.29
Provision & Write-off of Bad Debts
4.797.075.552.9635.9570.22
Other Operating Activities
101.58115.67136.1166.02142.83127.31
Change in Accounts Receivable
8.62-49.5126.37121.2-60.5417.56
Change in Inventory
-161.91-35.97-80.0720.98-57.719.28
Change in Accounts Payable
188.982.2578.32-17.1259.681
Change in Other Net Operating Assets
---16.53-0.0316.56-
Operating Cash Flow
382.22233.9164.71-3.5415.81156.83
Operating Cash Flow Growth
32.32%42.01%---89.92%226.79%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-360.3-234.35-115.84-81.76-189.85-199
Sale of Property, Plant & Equipment
0.80.4345.531.0747.490.14
Cash Acquisitions
-----0.1-3.92
Divestitures
0.41.85---1.93-
Investment in Securities
-6.385.40.3228.37195.2921.2
Other Investing Activities
2.32--0.030.823.19
Investing Cash Flow
-363.17-226.67-70.01147.7151.72-178.39

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-28.5190.4125-
Long-Term Debt Issued
-1,5781,3391,378537.291,457
Total Debt Issued
1,5181,6061,5291,390542.291,457
Short-Term Debt Repaid
--84.5-207.4---
Long-Term Debt Repaid
--1,638-1,541-1,173-495.09-1,644
Total Debt Repaid
-1,907-1,723-1,749-1,173-495.09-1,644
Net Debt Issued (Repaid)
-388.97-116.7-219.55216.2547.2-187.81
Issuance of Common Stock
--2.14---
Common Dividends Paid
-96.31-94.84-111.75-117.9-114.8-115.64
Other Financing Activities
214.95187.57-16.33-2.5-3.549.79
Financing Cash Flow
-270.33-23.96-345.4895.85-71.11-253.67

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-4.061.483.380.922.07-1.58
Net Cash Flow
-255.33-15.25-247.4240.94-1.51-276.81

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
21.92-0.4548.87-85.3-174.04-42.17
Free Cash Flow Growth
-84.18%-----
Free Cash Flow Margin
1.98%-0.05%8.28%-19.77%-24.71%-5.73%
Free Cash Flow Per Share
0.02-0.06-0.10-0.20-0.04
Levered Free Cash Flow
-77.5-98.7161.55-54.53-176.94-190.2
Unlevered Free Cash Flow
-47.8-37.44128.1120.76-112.4-135.25

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
32.36.37.4259.6841.665.12
Change in Working Capital
42.18-74.777.7124.3-42.62121.2